Posted by Michael Wonder on 07 Apr 2021
Rare Disease Therapeutics announces new expanded FDA approved indication for antivenom Anavip for treatment of North American Pit Viper envenomation
5 April 2021 - Anavip now indicated for management of adult and paediatric patients with all North American Pit Viper envenomation, including rattlesnake, copperhead, and cottonmouth/water moccasin bites.
Rare Disease Therapeutics today announced that the United States FDA approved a new expanded indication for Anavip (crotalidae immune F(ab’)2 (equine)), an equine-derived antivenin, for the management of adult and paediatric patients with North American Pit Viper envenomation.
